RECRUITING
I'm interested ...!!
Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks
Conditions:
🦠 Psoriasis
🗓️ Study Start (Actual) 16 January 2019
🗓️ Primary Completion (Estimated) 15 September 2019
✅ Study Completion (Estimated) 15 December 2019
👥 Enrollment (Estimated) 30
🔬 Study Type INTERVENTIONAL
📊 Phase PHASE4
Locations:
📍 East Windsor, New Jersey, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • * Male or female adult ≥ 18 years of age;
    • * Diagnosis of chronic plaque-type
    • * Patient with 2-10% BSA
    • * Physician Global Assessment of 2 or greater
    • * Patient has been treated with etanercept or adalimumab for a minimum of 24 weeks

    Exclusion Criteria:

    • * ˂2 or \>10% BSA
    • * PGA \<2
    • * Patient not receiving etanercept or adalimumab, or receiving etanercept or adalimumab \<24weeks
Ages Eligible for Study: 18 Years to N/A (ADULT, OLDER_ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 29 January 2019
  • First Submitted that Met QC Criteria 31 January 2019
  • First Posted 4 February 2019

Study Record Updates

  • Last Update Submitted that Met QC Criteria 31 January 2019
  • Last Update Posted 4 February 2019
  • Last Verified January 2019
I'm interested ...!!